Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

CalciMedica Inc CALC

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous (IV) formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase 2b trial (called CARPO - NCT04681066) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase 1/2 asparaginase induced pancreatic toxicity (AIPT) study (called CRSPA - NCT04195347).


NDAQ:CALC - Post by User

Post by uptowndog1on Apr 15, 2021 10:56am
378 Views
Post# 33000258

Globe says Graycliff, others hit by shady promotions

Globe says Graycliff, others hit by shady promotionsGlobe says Graycliff, others hit by shady promotions 2021-04-15 08:44 ET - In the News Also In the News (C-CRS) Crestview Exploration Inc Also In the News (C-VALU) Valorem Resources Inc The Globe and Mail reports in its Thursday, April 15, edition that Robert Caines felt sick when he spotted an article on the Internet hyping Graycliff Exploration ($1.01). The Globe's Niall McGee writes that on Monday The Financial News (FN) website said Graycliff had $500-million worth of gold reserves, and its stock was set to skyrocket. The post on Graycliff was almost identically worded to one Mr. Caines saw in February that him and his family to buy shares in Crestview Exploration. After they had held Crestview for a few weeks, the stock crashed for no apparent reason. Mr. Caines believes Crestview was the target of a "pump and dump." The Caines family cashed out of Crestview with a $16,000 loss. This week, Graycliff and Valorem Resources, were targeted on the same website that promoted Crestview in February. On Monday morning, after FN touted Graycliff, its shares ran up by 50 per cent. Near midday, FN suddenly dropped its promotional push on Graycliff, and shifted its efforts to Valorem. Right away, Graycliff shares started tanking, and Valorem went parabolic. Mr. Caines says, "They're really scamming people, taking everyone's money." He says, "The RCMP should know about this."
<< Previous
Bullboard Posts
Next >>